Sources: http://www.tempointeraktif.com/hg/kesehatan/2009/05/05/brk 0.20090505 to 174,445, id.html
TEMPO Interactive, New York: An analysis of clinical data indicates that vitamin E, and drugs that reduce general inflammation, may slow the decline in mental and physical abilities in people with Alzheimer's disease over the long term.
"We believe the potential benefit of vitamin E on slowing decline in the functions and benefits of a smaller, on cognitive decline in patients with Alzheimer's disease," Dr. Alireza Atri told Reuters.
Atri, at Massachusetts General Hospital, Bedford VA Medical Center and Harvard Medical School, Boston, led the National Institutes of Health sponsored the study. The findings were reported at the annual meeting of the American Geriatrics in Chicago, from data on 540 patients treated at the hospital.
All patients received standard treatment with drugs to help Alzheimer's patients. As part of their clinical care, 208 patients also took vitamin E but no anti-inflammatory, 49 took an anti-inflammatory but no vitamin E, 177 took both vitamin E and anti-inflammatory, and do not take 106.
While the daily dose of vitamin E ranged from 200 to 2000 units, the majority of patients given high doses that ranged from 800 units to 1,000 units per day twice a day.
Each patient on tests of cognitive performance and their ability to perform functions such as daily personal care and assessed every six months. After an average of three years, there is a slowing decline in function in patients taking vitamin E.
TEMPO Interactive, New York: An analysis of clinical data indicates that vitamin E, and drugs that reduce general inflammation, may slow the decline in mental and physical abilities in people with Alzheimer's disease over the long term.
"We believe the potential benefit of vitamin E on slowing decline in the functions and benefits of a smaller, on cognitive decline in patients with Alzheimer's disease," Dr. Alireza Atri told Reuters.
Atri, at Massachusetts General Hospital, Bedford VA Medical Center and Harvard Medical School, Boston, led the National Institutes of Health sponsored the study. The findings were reported at the annual meeting of the American Geriatrics in Chicago, from data on 540 patients treated at the hospital.
All patients received standard treatment with drugs to help Alzheimer's patients. As part of their clinical care, 208 patients also took vitamin E but no anti-inflammatory, 49 took an anti-inflammatory but no vitamin E, 177 took both vitamin E and anti-inflammatory, and do not take 106.
While the daily dose of vitamin E ranged from 200 to 2000 units, the majority of patients given high doses that ranged from 800 units to 1,000 units per day twice a day.
Each patient on tests of cognitive performance and their ability to perform functions such as daily personal care and assessed every six months. After an average of three years, there is a slowing decline in function in patients taking vitamin E.